EC Number   |
Application |
Reference |
|---|
    1.4.3.4 | analysis |
both (R)-(-)- and (S)-(+)-1-(1-[11C]methyl-1H-pyrrol-2-yl)-2-phenyl-2-(1-pyrrolidinyl)ethanone are very promising tracers for positron emission tomography of the MAO-A enzyme in brain. The carbon-11-labeling reaction is fairly simple and robust. Yields of more than 1 GBq are routinely obtained and with high specific activity of the final product. The metabolism of (R)-(-)- and (S)-(+)-1-(1-[11C]methyl-1H-pyrrol-2-yl)-2-phenyl-2-(1-pyrrolidinyl)ethanone is relatively slow in plasma of living pigs, in contrast to [11C]harmine, which is difficult to detect in plasma at times after 10 min. Parametric maps of [11C](R)-(-)- and (S)-(+)-1-(1-[11C]methyl-1H-pyrrol-2-yl)-2-phenyl-2-(1-pyrrolidinyl)ethanone binding are qualitatively very comparable to those of [11C]harmine |
688271 |
| 1.4.3.4 | analysis |
kinetic assay for detection of MAO-A inhibitors in plant extracts using recombinant MAO-A expressed as GST-fusion protein in yesat |
656957 |
| 1.4.3.4 | analysis |
on-line immobilized enzyme reactors can be used for the on-line screening of substances for MAO-A and substrate/inhibitor properties |
656361 |
| 1.4.3.4 | analysis |
on-line immobilized enzyme reactors can be used for the on-line screening of substrances for MAO-A and substrate/inhibitor properties |
656361 |
| 1.4.3.4 | drug development |
active monoamine oxidase inhibitors represent suitable leads for the development of drugs for neurodegenerative and neuropsychiatric disorders such as Parkinson's disease and depression. Monoamine oxidase inhibitors are also of interest for the treatment of prostate cancer, certain types of cardiomyopathies and Alzheimer's disease |
764555 |
| 1.4.3.4 | drug development |
dual-target-directed drugs, compounds that inhibit MAO-B and antagonize A2A receptors, may have value in the management of Parkinson's disease, overview |
705940 |
| 1.4.3.4 | drug development |
indole and benzofuran derivatives are promising reversible MAO-B inhibitors with a possible role in the treatment of neurodegenerative diseases such as Parkinsons disease |
711911 |
| 1.4.3.4 | drug development |
MAO-A is a target for a series of therapeutically valuable drugs. Thus, selective MAO-A inhibitors are used as antidepressants |
702639 |
| 1.4.3.4 | drug development |
MAO-B is a target for a series of therapeutically valuable drugs. Thus, selective MAO-B inhibitors are used in the treatment of Parkinsons disease |
702639 |
| 1.4.3.4 | medicine |
a significant association is found between the G-allele of 941G/T in MAO-A and attention deficit hyperactivity disorder (ADHD) |
685838 |
